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! "#Due to the lack of paediatric licensed formulations, children are often treated 
with individualized pharmacy5compounded adult medication. An international web5based 
survey about the types of medication in children with adrenal insufficiency (AI) revealed that 
the majority of paediatric physicians are using pharmacy5compounded medication to treat 
children with AI. Observations of loss of therapy control in children with congenital adrenal 
hyperplasia with compounded hydrocortisone capsules and regained control after prescribing 
a new hydrocortisone batch led to this “real world” evaluation of pharmacy5compounded 
paediatric hydrocortisone capsules. 
$	Capsule samples were collected randomly from volunteering parents of treated 
children suffering from congenital adrenal hyperplasia from all over Germany. Analysis of 
net mass and hydrocortisone content by HPLC5UV (high performance liquid 
chromatography) method were performed based on the European Pharmacopeia. 
%In total 61 batches were sent in. 5 batches could not be analyzed because of missing 
dose information, insufficient number of capsules or were not possible to be evaluated. 56 
batches containing 1125 capsules were evaluated. 21.4% of the batches revealed 
insufficiency in uniformity of net mass or drug content and additional 3.6% failed because 
they did not contain the labelled drug. 
		Compounded medication is a possible cause of variation of steroid doses in 
children with adrenal insufficiency or congenital adrenal hyperplasia, putting these 
vulnerable patients at risk of poor disease control and adrenal crisis. These data may apply to 
other individualized compounded oral medication as well, emphasizing the need for 
development of licensed paediatric formulations approved by regulatory authorities.  
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A five5year5old girl with congenital adrenal hyperplasia (CAH) and no history of non5
compliance developed accelerated growth and elevated androgens. Visual inspection of her 
compounded hydrocortisone capsules showed variable capsule filling (Figure 1); assuming 
similar fluctuations in hydrocortisone content as in filling, a new batch was prescribed which 
immediately improved disease control. Based on this observation, we undertook a “real 
world” evaluation of pharmacy5compounded paediatric hydrocortisone capsules. 
Compounding adult medication is commonly used to provide paediatric doses. An 
international web5based survey was distributed through the newsletter of the European 
Society of Paediatric Endocrinology (ESPE) to specify their current treatment of adrenal 
insufficiency in neonates and children 
1
. 67 participants from 16 countries, mostly from 
Europe, stated the use of divided licensed adult medication (60%) as off5label and 
prescription of individualized capsules (55%) as unlicensed use 
1
. The prescribed dosage 
varied from 0.5mg to 5.0mg with the vast majority of doses being 1.0mg and 2.0mg. 
Compounding is regulated by less stringent criteria than those used for licensed drugs as 
compounded drugs are neither approved by the EMA (European medicines agency) or FDA 
(Food and Drug Administration) nor required to demonstrate efficacy 
2
. There is also 
exemption from GMP (Good Manufacturing Practice) requirements in manufacture for 
compounded medicines which increases the risks of inaccurate dosing 
2
. Compounding is by 
definition an unlicensed use which accounts for up to 60% of medicines administered to 
children in Europe and the United States 
3, 4
.  The European Pharmacopeia (EP) is a reference 
work giving common standards for the quality of medicines and their components to provide 
a basis for the safe use of medicines. The EP contains acceptance criteria for mass and 
content uniformity to evaluate batches or single capsules 
5
.  
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Here we report a problem with dosing when using compounded hydrocortisone in children 
suffering from adrenal insufficiency and congenital adrenal hyperplasia. These patients 
require hydrocortisone replacement therapy to avoid life5threatening adrenal crises and 
careful titration of therapy to control androgen excess and optimize growth and development. 
The lowest dose available of hydrocortisone in the USA is a 5.0mg tablet and in Europe a 
10.0mg  tablet.  However, the average dose used in paediatrics is 2.0mg with doses as low as 
0.5mg required for neonates and infants 
1
. There is therefore a necessity to compound 
hydrocortisone for paediatric use. Use of compounded hydrocortisone medication in children 
is thereby unlicensed as well as off5label treatment. Hydrocortisone has a narrow therapeutic 
index and patients with CAH have poor health outcomes in adulthood on current 
glucocorticoid treatment in part related to treatment in childhood 
6, 7
. Poor compliance is 
often blamed for poor disease control in children with CAH. However, as we report here this 
might also be due to the lack of content uniformity in compounded hydrocortisone 
preparations. 

$	  
A newsletter from the German CAH5patient organisation, as well as information provided by 
treating physicians during regular appointments was used to ask parents and caregivers to 
participate in this study.  Parents or caregivers were invited to send 20 capsules of their 
child’s compounded hydrocortisone medication to our laboratory. The capsules received for 
this study were prescribed for CAH5patients aged 0514 years. No information about sex or 
other clinical variables were collected. 61 batches (ncapsules: 1210, mean 20/batch) from 11 of 
16 federal states in Germany from 35 families and produced in 37 different pharmacies were 
examined. Net mass of capsule content was calculated by weighing each capsule and 
subtracting the nominal casing mass from the total mass. To calculate uniformity, mean net 
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mass of each batch and deviations from this mean net mass per capsule were calculated. To 
evaluate the  hydrocortisone content, a HPLC5UV method was developed 
8
 and validated 
according to EMA Guideline 
(http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC
500109686.pdf Published 2012. Accessed September 2, 2013) 
9
.
 
To calculate uniformity of 
hydrocortisone content, mean batch content and deviations from these means per capsule 
were calculated. The results were evaluated based on the EP acceptance criteria for mass and 
content uniformity 
5
. A batch failed if >10% exceeds tolerable limits and ≥1 capsule exceeds 
non5tolerable limits 
5
. The limits used were 10% and 20% for mass and 15 and 25% for 
content. The study was approved by the institutional ethics committee (EA2/134/12). Study 
participants received a results information letter relating to their supplied batch. 
 
%  
Of 61 capsule batches that were received for analysis, 5 batches were excluded from all 
further analysis 5 one of them because surprisingly olive oil had been used as excipient in the 
capsule which leaked out of the capsules and neither net mass nor drug content could be 
measured; one batch had no dosing information provided and in three batches the number of 
capsules was too small for evaluation. 56 batches containing 1125 capsules were further 
evaluated in detail and the results for individual capsules evaluated are shown in the Table 1. 
Two batches contained no hydrocortisone at all but as the primary criteria are based on 
uniformity analysis of mass and content, these were included in the analysis and passed the 
content criteria with a homogenous result of 0% hydrocortisone in all capsules. Batch 
analysis revealed the following results: for drug content 49 batches (87.5%) fulfilled the 
acceptance criteria based on the EP guidelines , whilst 7 batches (12.5%) failed. Extreme 
hydrocortisone containing batches, showed deviations from mean drug content of ±30% 5 
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200%. For net mass 47 batches (84%) fulfilled the acceptance criteria, whilst 9 batches (16%) 
failed. Thus, of the compounded capsules that contained hydrocortisone, 21.4% of batches 
revealed a failure in the acceptance criteria in net mass or drug content: 3 batches with 
content deviations only (5.4%), 5 batches with net mass deviation only (9.0%) and 4 batches 
with both content and net mass deviation (7.1%). In summary 21.4% failed the uniformity 
analysis and 3.6% did not contain the labelled steroid at all, totaling up to 25% of batches 
which cannot ensure safe therapy for the patients.  

'	  
In our “real world” analysis, every 4
th
 batch of compounded hydrocortisone revealed a failure 
of the acceptance criteria based on the European Pharmacopeia. In extreme batches that 
contained hydrocortisone, the drug content deviated from mean drug content by ±30% 5 
200% and some batches did not contain any detectable hydrocortisone, but another 
glucocorticoid, despite being labelled as such. 
Here we report a problem with dosing when using compounded hydrocortisone in children 
suffering from adrenal insufficiency and congenital adrenal hyperplasia (CAH). These 
patients require hydrocortisone replacement therapy to avoid life5threatening adrenal crises 
and careful titration of therapy to control androgen excess and optimize growth and 
development. The lowest dose available for hydrocortisone in the USA is a 5.0mg tablet and 
a 10.0mg tablet in Europe.  However, the average dose used in paediatrics is 2.0mg with 
doses as low as 0.5mg required for neonates and infants 
1
. There is therefore a necessity to 
compound hydrocortisone for paediatric use. Hydrocortisone has a narrow therapeutic index 
and patients with CAH have poor health outcomes in adulthood on current glucocorticoid 
treatment in part related to treatment in childhood 
6, 7
. Poor compliance is often blamed for 
poor disease control in children with CAH and this causes considerable distress to children 
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and parents. However, as we show here this might also be due to the lack of content 
uniformity in compounded hydrocortisone.  
The advantage of our study is that it was done as a “real world” analysis of what medication 
patients receive from their local pharmacy. A limitation of our study is that it was undertaken 
in only one country, however the regulations used apply across Europe and are similar to 
those in USA. Based on our international web5based survey of medication it is common 
paediatric practice in most countries to use divided licensed adult medication (60%) or 
prescribe individualized capsules (55%)
1
. Sample collection was voluntary and not designed 
to be representative, thereby we cannot exclude a possible sampling bias because parents in 
doubt (e.g. receiving oily capsules) of the child’s medication might be more likely to 
participate.  
There are no obligatory quality checks of pharmacy5compounded medication regarding drug 
content. Pharmacies may take part in a voluntary external control program but these tests are 
expensive and participation is not monitored or reported. As the regulations for pharmacy5
compounded hydrocortisone are identical to those for other pharmacy5produced medication 
our findings may also be applicable to other compounded medication. Further studies on a 
broader range of compounded paediatric medication are needed to evaluate the inherent risk 
of significant dosing errors caused by e.g. adherence or the pharmaceutic compounding 
process. This risk may frequently escape paediatrician’s notice when dealing with therapy 
failure in paediatric patients. 
 
Our results demonstrate that variations in pharmacy5compounded medication might cause 
poor disease control in children. In newborns and infants precise dosing of hydrocortisone at 
low dose is essential, otherwise these vulnerable patients are at risk of poor disease control 
Page 7 of 15
8 
 
and potential adrenal crisis. There is a need for the development of licensed paediatric 
formulations approved by regulatory authorities such as the EMA and FDA.  
 
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Figure 1: A batch of compounded hydrocortisone capsules dispensed for a child with CAH. 
Each capsule is meant to contain the same dose but as can be seen visually there is great 
variation in capsule content.   
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: Deviations per capsule from either mean net mass or mean drug content: 
Deviation ranges Number (%)  of capsules per deviation range with respect to 
from mean of batch mean net mass mean drug content 
< ±10% 1032 (95%) 953 (84.7%) 
≥ ±10% ) < ±20%  50 (4.6%) 102 (9.1%) 
≥ ±20% 3 (0.3%) 70 (6.2%) 
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